Efficacy of Hemobahn® in the Treatment of Superficial Femoral Artery Lesions in Patients with Acute or Critical Ischemia: A Comparative Study with Claudicants
Male
Superficial femoral artery
Arterial Occlusive Diseases
Blood Vessel Prosthesis Implantation
03 medical and health sciences
0302 clinical medicine
Ischemia
Risk Factors
Humans
Stent-graft
Aged
Medicine(all)
Aged, 80 and over
Poor outflow
Hemobahn
Critical limb ischemia
Intermittent Claudication
Middle Aged
Limb Salvage
Blood Vessel Prosthesis
3. Good health
Femoral Artery
Lower Extremity
Acute Disease
Female
Stents
Occlusive disease
DOI:
10.1016/j.ejvs.2005.04.027
Publication Date:
2005-06-06T20:57:20Z
AUTHORS (7)
ABSTRACT
To assess the results of covered stents in the treatment of superficial femoral artery (SFA) occlusive disease.From July 2000 till June 2003, 32 patients (34 limbs) were scheduled for procedures including Hemobahn deployment in the SFA. Indication for treatment was claudication (group I, N=15 patients and 16 limbs, 31.2% occlusions) or critical and acute ischemia (group II, N=17 patients and 18 limbs, 61.1% occlusions). TASC D SFA lesions were excluded. No limb artery was patent pre-operatively in 19% and 89% of limbs in groups I and II, respectively (p=0.00001).Outflow procedures were performed simultaneously in one limb in group I and 12 in group II (p=0.0003). The technical, hemodynamic and clinical success rates were 100, 100 and 94.1%, respectively. Mean follow-up was 18.1 months. Primary patency rates at 12 months were 81.3+/-10.6% in group I and 88.6+/-9.0% in group II (p=0.547). At 12 months, the secondary patency and limb salvage rates were, respectively, 87.5+/-8.9 and 100% in group I and 87.5+/-8.93 and 94.45+/-6.71% in group II.Treatment of SFA occlusive lesions (excluding TASC D lesions) with the Hemobahn covered stent yielded good results for both claudicants with good outflow and patients with critical or acute ischemia with bad outflow, if concomitant outflow-improving procedures were performed.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (19)
CITATIONS (35)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....